Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.
Chin Clin Oncol
; 5(1): 5, 2016 Feb.
Article
em En
| MEDLINE
| ID: mdl-26932429
Palavras-chave
CD137 is a costimulatory receptor that belongs to the tumor necrosis factor receptor (TNFR) superfamily. CD137 is expressed on T cell, activated NK cells and other immune cells. We recently showed that an agonistic anti-CD137 mAb activates NK cells, resul; Efficacy of anti-CD137 mAb was examined by in vitro and in vivo experiments. Clinical trials of anti-CD137 mAb are also on-going.; Monoclonal antibodies are an invaluable therapeutic class when it comes to cancer therapy. One of the primary mechanisms of anti-tumor activity of monoclonal antibodies is antibody dependent cell-mediated cytotoxicity (ADCC) mediated by natural killer (NK; We discuss some of the promising strategies that could potentially enhance ADCC with anti-CD137 mAbs.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Membro 9 da Superfamília de Receptores de Fatores de Necrose Tumoral
/
Sistema Imunitário
/
Imunoterapia
/
Anticorpos Monoclonais
/
Citotoxicidade Celular Dependente de Anticorpos
/
Neoplasias
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Chin Clin Oncol
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Japão